Sign In
Buy ENTX
$1.22
-0.0300 (-2.40%)
At Close: Jun 03, 2026
ENTX Stock Price Increased 70.79%: Why It Happened
05:02am, Saturday, 13'th Mar 2021
The stock price of Entera Bio Ltd (NASDAQ: ENTX) increased by 70.79% yesterday. This is why it happened.
Halted Stocks: What to Know as ENTX Stock Faces Trading Halts
10:54am, Friday, 12'th Mar 2021
ENTX stock continues to sky rocket, leading investors to question halted stocks. Here's what you should know now.
ENTX Stock Price Increases Over 40% Pre-Market: Why It Happened
06:09am, Friday, 12'th Mar 2021
The stock price of Entera Bio Ltd (Nasdaq: ENTX) has increased by over 40% pre-market. This is why it happened.
Entera Bio to Report Financial Results for the Year Ended December 31, 2020 on March 18, 2021
04:15pm, Thursday, 11'th Mar 2021
BOSTON and JERUSALEM, March 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business
Entera Bio Stock Skyrockets On Positive EB613 Biomarker Analysis Data In Osteoporosis Study
09:23am, Thursday, 11'th Mar 2021
Entera Bio Ltd (NASDAQ: ENTX) is soaring in the premarket in reaction to positive topline data from the Phase 2 trial of EB613 in postmenopausal female subjects with osteoporosis (low bone mineral
ENTX Stock Price Increases Over 200% Pre-Market: Why It Happened
09:12am, Thursday, 11'th Mar 2021
The stock price of Entera Bio Ltd. (NASDAQ: ENTX) has increased by over 200% pre-market.
Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data
08:30am, Thursday, 11'th Mar 2021
‒ Trial Met Primary Endpoint of Significant Increase in P1NP Based on Final Analysis of 3 Month Data ‒ ‒ Final Analysis of 6-Month Data , Including Change in Bone Mineral Density, Expected in Q2
Entera Bio Ltd. (ENTX) CEO Roger Garceau on Q3 2020 Results - Earnings Call Transcript
10:56am, Thursday, 19'th Nov 2020
Entera Bio Ltd. (ENTX) CEO Roger Garceau on Q3 2020 Results - Earnings Call Transcript
Entera Bio Ltd Announces Third Quarter 2020 Financial Results and Provides Clinical Update
06:30am, Thursday, 19'th Nov 2020
‒ Completed E nrollment in Phase 2 Clinical Trial of EB613, P ositioned as the F irst P otential O ral B one B uilding P roduct to T reat O steoporosis ‒ ‒ Positive Interim 6-Month Bone Mineral
Entera Bio to Report Third Quarter 2020 Business and Financial Results on November 19, 2020
07:30am, Friday, 13'th Nov 2020
BOSTON JERUSALEM, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and f
Entera Osteoporosis Trial, And Other News: The Good, Bad And Ugly Of Biopharma
06:48am, Monday, 24'th Aug 2020
Entera Bio reports encouraging data from osteoporosis trial. Alkermes progresses Phase 2 trial for ALKS 4230.
Entera Bio Ltd. (ENTX) Interim CEO Roger Garceau on Q2 2020 Results - Earnings Call Transcript
02:00pm, Thursday, 20'th Aug 2020
Entera Bio Ltd. (NASDAQ:ENTX) Q2 2020 Results Conference Call August 20, 2020 08:30 AM ET Company Participants Jon Lieber - U.S.
Entera Bio to Report Second Quarter 2020 Business and Financial Results on August 20, 2020
12:30pm, Monday, 17'th Aug 2020
BOSTON and JERUSALEM, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business a
Entera Bio Announces Management Changes
12:30pm, Monday, 10'th Aug 2020
BOSTON and JERUSALEM, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that its Board of D
Entera Bio to Present at BTIG’s Virtual Biotechnology Conference
12:30pm, Wednesday, 05'th Aug 2020
BOSTON and JERUSALEM, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its mana
